nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2C8—Levothyroxine—hypothyroidism	0.136	0.227	CbGbCtD
Buprenorphine—CYP2C8—Liotrix—hypothyroidism	0.133	0.222	CbGbCtD
Buprenorphine—ABCB1—Liothyronine—hypothyroidism	0.0924	0.154	CbGbCtD
Buprenorphine—ABCB1—Levothyroxine—hypothyroidism	0.0924	0.154	CbGbCtD
Buprenorphine—ABCB1—Liotrix—hypothyroidism	0.0901	0.15	CbGbCtD
Buprenorphine—CYP3A4—Levothyroxine—hypothyroidism	0.0553	0.0923	CbGbCtD
Buprenorphine—Retching—Levothyroxine—hypothyroidism	0.0125	0.0407	CcSEcCtD
Buprenorphine—Retching—Dextrothyroxine—hypothyroidism	0.0125	0.0407	CcSEcCtD
Buprenorphine—Warmth—Liotrix—hypothyroidism	0.00984	0.0322	CcSEcCtD
Buprenorphine—Retching—Liotrix—hypothyroidism	0.00916	0.0299	CcSEcCtD
Buprenorphine—OPRM1—nerve—hypothyroidism	0.00544	0.065	CbGeAlD
Buprenorphine—CYP2C19—urine—hypothyroidism	0.00543	0.0649	CbGeAlD
Buprenorphine—Angina pectoris—Liothyronine—hypothyroidism	0.00529	0.0173	CcSEcCtD
Buprenorphine—CYP1A2—urine—hypothyroidism	0.00444	0.053	CbGeAlD
Buprenorphine—Cyanosis—Liotrix—hypothyroidism	0.00442	0.0144	CcSEcCtD
Buprenorphine—OPRL1—adrenal gland—hypothyroidism	0.00429	0.0512	CbGeAlD
Buprenorphine—OPRL1—blood—hypothyroidism	0.00429	0.0512	CbGeAlD
Buprenorphine—CYP2C9—urine—hypothyroidism	0.00421	0.0503	CbGeAlD
Buprenorphine—Wheezing—Dextrothyroxine—hypothyroidism	0.00413	0.0135	CcSEcCtD
Buprenorphine—Wheezing—Levothyroxine—hypothyroidism	0.00413	0.0135	CcSEcCtD
Buprenorphine—Feeling hot—Liotrix—hypothyroidism	0.00399	0.013	CcSEcCtD
Buprenorphine—Abscess—Liotrix—hypothyroidism	0.00396	0.0129	CcSEcCtD
Buprenorphine—Coma—Dextrothyroxine—hypothyroidism	0.00389	0.0127	CcSEcCtD
Buprenorphine—Coma—Levothyroxine—hypothyroidism	0.00389	0.0127	CcSEcCtD
Buprenorphine—OPRL1—testis—hypothyroidism	0.00355	0.0424	CbGeAlD
Buprenorphine—Disorientation—Dextrothyroxine—hypothyroidism	0.00345	0.0113	CcSEcCtD
Buprenorphine—Disorientation—Levothyroxine—hypothyroidism	0.00345	0.0113	CcSEcCtD
Buprenorphine—Hypertension—Liothyronine—hypothyroidism	0.00327	0.0107	CcSEcCtD
Buprenorphine—CYP3A4—urine—hypothyroidism	0.00321	0.0384	CbGeAlD
Buprenorphine—CYP2D6—urine—hypothyroidism	0.00316	0.0378	CbGeAlD
Buprenorphine—Affect lability—Levothyroxine—hypothyroidism	0.00304	0.00993	CcSEcCtD
Buprenorphine—Affect lability—Dextrothyroxine—hypothyroidism	0.00304	0.00993	CcSEcCtD
Buprenorphine—Wheezing—Liotrix—hypothyroidism	0.00304	0.00993	CcSEcCtD
Buprenorphine—Tachycardia—Liothyronine—hypothyroidism	0.00302	0.00986	CcSEcCtD
Buprenorphine—Mood swings—Levothyroxine—hypothyroidism	0.00293	0.00956	CcSEcCtD
Buprenorphine—Mood swings—Dextrothyroxine—hypothyroidism	0.00293	0.00956	CcSEcCtD
Buprenorphine—Hypotension—Liothyronine—hypothyroidism	0.00289	0.00944	CcSEcCtD
Buprenorphine—Dehydration—Dextrothyroxine—hypothyroidism	0.00287	0.00939	CcSEcCtD
Buprenorphine—Dehydration—Levothyroxine—hypothyroidism	0.00287	0.00939	CcSEcCtD
Buprenorphine—Coma—Liotrix—hypothyroidism	0.00286	0.00934	CcSEcCtD
Buprenorphine—Muscular weakness—Levothyroxine—hypothyroidism	0.00272	0.0089	CcSEcCtD
Buprenorphine—Muscular weakness—Dextrothyroxine—hypothyroidism	0.00272	0.0089	CcSEcCtD
Buprenorphine—Dysphagia—Levothyroxine—hypothyroidism	0.00267	0.00872	CcSEcCtD
Buprenorphine—Dysphagia—Dextrothyroxine—hypothyroidism	0.00267	0.00872	CcSEcCtD
Buprenorphine—Angina pectoris—Dextrothyroxine—hypothyroidism	0.0026	0.0085	CcSEcCtD
Buprenorphine—Angina pectoris—Levothyroxine—hypothyroidism	0.0026	0.0085	CcSEcCtD
Buprenorphine—Disorientation—Liotrix—hypothyroidism	0.00254	0.0083	CcSEcCtD
Buprenorphine—Body temperature increased—Liothyronine—hypothyroidism	0.00244	0.00798	CcSEcCtD
Buprenorphine—Weight decreased—Levothyroxine—hypothyroidism	0.00241	0.00789	CcSEcCtD
Buprenorphine—Weight decreased—Dextrothyroxine—hypothyroidism	0.00241	0.00789	CcSEcCtD
Buprenorphine—Sweating—Levothyroxine—hypothyroidism	0.00228	0.00746	CcSEcCtD
Buprenorphine—Sweating—Dextrothyroxine—hypothyroidism	0.00228	0.00746	CcSEcCtD
Buprenorphine—Affect lability—Liotrix—hypothyroidism	0.00224	0.00731	CcSEcCtD
Buprenorphine—UGT1A9—liver—hypothyroidism	0.00219	0.0261	CbGeAlD
Buprenorphine—Mood swings—Liotrix—hypothyroidism	0.00215	0.00703	CcSEcCtD
Buprenorphine—Dehydration—Liotrix—hypothyroidism	0.00211	0.0069	CcSEcCtD
Buprenorphine—Muscular weakness—Liotrix—hypothyroidism	0.002	0.00655	CcSEcCtD
Buprenorphine—Flushing—Dextrothyroxine—hypothyroidism	0.00198	0.00648	CcSEcCtD
Buprenorphine—Flushing—Levothyroxine—hypothyroidism	0.00198	0.00648	CcSEcCtD
Buprenorphine—Abdominal distension—Liotrix—hypothyroidism	0.00198	0.00646	CcSEcCtD
Buprenorphine—Dysphagia—Liotrix—hypothyroidism	0.00196	0.00642	CcSEcCtD
Buprenorphine—Bronchospasm—Liotrix—hypothyroidism	0.00193	0.00631	CcSEcCtD
Buprenorphine—Angina pectoris—Liotrix—hypothyroidism	0.00191	0.00625	CcSEcCtD
Buprenorphine—CYP2C18—liver—hypothyroidism	0.00191	0.0228	CbGeAlD
Buprenorphine—Bronchitis—Liotrix—hypothyroidism	0.00189	0.00617	CcSEcCtD
Buprenorphine—Tension—Dextrothyroxine—hypothyroidism	0.00182	0.00596	CcSEcCtD
Buprenorphine—Tension—Levothyroxine—hypothyroidism	0.00182	0.00596	CcSEcCtD
Buprenorphine—CYP3A7—liver—hypothyroidism	0.00182	0.0217	CbGeAlD
Buprenorphine—Nervousness—Levothyroxine—hypothyroidism	0.00181	0.0059	CcSEcCtD
Buprenorphine—Nervousness—Dextrothyroxine—hypothyroidism	0.00181	0.0059	CcSEcCtD
Buprenorphine—Weight decreased—Liotrix—hypothyroidism	0.00178	0.0058	CcSEcCtD
Buprenorphine—Tremor—Levothyroxine—hypothyroidism	0.00174	0.00569	CcSEcCtD
Buprenorphine—Tremor—Dextrothyroxine—hypothyroidism	0.00174	0.00569	CcSEcCtD
Buprenorphine—Agitation—Dextrothyroxine—hypothyroidism	0.00171	0.00559	CcSEcCtD
Buprenorphine—Agitation—Levothyroxine—hypothyroidism	0.00171	0.00559	CcSEcCtD
Buprenorphine—Angioedema—Dextrothyroxine—hypothyroidism	0.0017	0.00555	CcSEcCtD
Buprenorphine—Angioedema—Levothyroxine—hypothyroidism	0.0017	0.00555	CcSEcCtD
Buprenorphine—Sweating—Liotrix—hypothyroidism	0.00168	0.00548	CcSEcCtD
Buprenorphine—Palpitations—Dextrothyroxine—hypothyroidism	0.00164	0.00537	CcSEcCtD
Buprenorphine—Palpitations—Levothyroxine—hypothyroidism	0.00164	0.00537	CcSEcCtD
Buprenorphine—OPRK1—cerebellum—hypothyroidism	0.00162	0.0193	CbGeAlD
Buprenorphine—Convulsion—Levothyroxine—hypothyroidism	0.00161	0.00527	CcSEcCtD
Buprenorphine—Convulsion—Dextrothyroxine—hypothyroidism	0.00161	0.00527	CcSEcCtD
Buprenorphine—Arthralgia—Dextrothyroxine—hypothyroidism	0.00158	0.00517	CcSEcCtD
Buprenorphine—Arthralgia—Levothyroxine—hypothyroidism	0.00158	0.00517	CcSEcCtD
Buprenorphine—Anxiety—Dextrothyroxine—hypothyroidism	0.00158	0.00516	CcSEcCtD
Buprenorphine—Anxiety—Levothyroxine—hypothyroidism	0.00158	0.00516	CcSEcCtD
Buprenorphine—Hypoaesthesia—Liotrix—hypothyroidism	0.00156	0.00511	CcSEcCtD
Buprenorphine—CYP3A7-CYP3A51P—liver—hypothyroidism	0.00155	0.0185	CbGeAlD
Buprenorphine—Confusional state—Dextrothyroxine—hypothyroidism	0.00153	0.005	CcSEcCtD
Buprenorphine—Confusional state—Levothyroxine—hypothyroidism	0.00153	0.005	CcSEcCtD
Buprenorphine—OPRM1—blood—hypothyroidism	0.00151	0.018	CbGeAlD
Buprenorphine—Shock—Dextrothyroxine—hypothyroidism	0.00149	0.00488	CcSEcCtD
Buprenorphine—Shock—Levothyroxine—hypothyroidism	0.00149	0.00488	CcSEcCtD
Buprenorphine—Tachycardia—Levothyroxine—hypothyroidism	0.00148	0.00484	CcSEcCtD
Buprenorphine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00148	0.00484	CcSEcCtD
Buprenorphine—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00147	0.00479	CcSEcCtD
Buprenorphine—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00147	0.00479	CcSEcCtD
Buprenorphine—Flushing—Liotrix—hypothyroidism	0.00146	0.00477	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00138	0.00452	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00138	0.00452	CcSEcCtD
Buprenorphine—Insomnia—Dextrothyroxine—hypothyroidism	0.00137	0.00449	CcSEcCtD
Buprenorphine—Insomnia—Levothyroxine—hypothyroidism	0.00137	0.00449	CcSEcCtD
Buprenorphine—Dyspnoea—Levothyroxine—hypothyroidism	0.00135	0.00442	CcSEcCtD
Buprenorphine—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00135	0.00442	CcSEcCtD
Buprenorphine—Flatulence—Liotrix—hypothyroidism	0.00135	0.00441	CcSEcCtD
Buprenorphine—Tension—Liotrix—hypothyroidism	0.00134	0.00439	CcSEcCtD
Buprenorphine—Dysgeusia—Liotrix—hypothyroidism	0.00134	0.00438	CcSEcCtD
Buprenorphine—Nervousness—Liotrix—hypothyroidism	0.00133	0.00434	CcSEcCtD
Buprenorphine—Fatigue—Dextrothyroxine—hypothyroidism	0.00131	0.00428	CcSEcCtD
Buprenorphine—Fatigue—Levothyroxine—hypothyroidism	0.00131	0.00428	CcSEcCtD
Buprenorphine—Vision blurred—Liotrix—hypothyroidism	0.00129	0.00421	CcSEcCtD
Buprenorphine—Tremor—Liotrix—hypothyroidism	0.00128	0.00419	CcSEcCtD
Buprenorphine—CYP2A6—liver—hypothyroidism	0.00126	0.0151	CbGeAlD
Buprenorphine—Agitation—Liotrix—hypothyroidism	0.00126	0.00411	CcSEcCtD
Buprenorphine—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00125	0.00409	CcSEcCtD
Buprenorphine—Feeling abnormal—Levothyroxine—hypothyroidism	0.00125	0.00409	CcSEcCtD
Buprenorphine—Angioedema—Liotrix—hypothyroidism	0.00125	0.00408	CcSEcCtD
Buprenorphine—OPRM1—testis—hypothyroidism	0.00125	0.0149	CbGeAlD
Buprenorphine—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00124	0.00406	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00124	0.00406	CcSEcCtD
Buprenorphine—CYP2A6—cerebellum—hypothyroidism	0.00123	0.0147	CbGeAlD
Buprenorphine—Syncope—Liotrix—hypothyroidism	0.00123	0.00401	CcSEcCtD
Buprenorphine—ABCG2—adrenal cortex—hypothyroidism	0.00122	0.0146	CbGeAlD
Buprenorphine—Palpitations—Liotrix—hypothyroidism	0.00121	0.00395	CcSEcCtD
Buprenorphine—Urticaria—Levothyroxine—hypothyroidism	0.00121	0.00394	CcSEcCtD
Buprenorphine—Urticaria—Dextrothyroxine—hypothyroidism	0.00121	0.00394	CcSEcCtD
Buprenorphine—Loss of consciousness—Liotrix—hypothyroidism	0.0012	0.00393	CcSEcCtD
Buprenorphine—Abdominal pain—Levothyroxine—hypothyroidism	0.0012	0.00392	CcSEcCtD
Buprenorphine—Body temperature increased—Levothyroxine—hypothyroidism	0.0012	0.00392	CcSEcCtD
Buprenorphine—Body temperature increased—Dextrothyroxine—hypothyroidism	0.0012	0.00392	CcSEcCtD
Buprenorphine—Abdominal pain—Dextrothyroxine—hypothyroidism	0.0012	0.00392	CcSEcCtD
Buprenorphine—Convulsion—Liotrix—hypothyroidism	0.00119	0.00387	CcSEcCtD
Buprenorphine—Hypertension—Liotrix—hypothyroidism	0.00118	0.00386	CcSEcCtD
Buprenorphine—ABCG2—heart—hypothyroidism	0.00118	0.0141	CbGeAlD
Buprenorphine—Chest pain—Liotrix—hypothyroidism	0.00116	0.00381	CcSEcCtD
Buprenorphine—Arthralgia—Liotrix—hypothyroidism	0.00116	0.00381	CcSEcCtD
Buprenorphine—Anxiety—Liotrix—hypothyroidism	0.00116	0.00379	CcSEcCtD
Buprenorphine—Confusional state—Liotrix—hypothyroidism	0.00113	0.00368	CcSEcCtD
Buprenorphine—Oedema—Liotrix—hypothyroidism	0.00112	0.00365	CcSEcCtD
Buprenorphine—Anaphylactic shock—Liotrix—hypothyroidism	0.00112	0.00365	CcSEcCtD
Buprenorphine—Infection—Liotrix—hypothyroidism	0.00111	0.00362	CcSEcCtD
Buprenorphine—Shock—Liotrix—hypothyroidism	0.0011	0.00359	CcSEcCtD
Buprenorphine—Tachycardia—Liotrix—hypothyroidism	0.00109	0.00356	CcSEcCtD
Buprenorphine—Asthenia—Dextrothyroxine—hypothyroidism	0.00109	0.00356	CcSEcCtD
Buprenorphine—Asthenia—Levothyroxine—hypothyroidism	0.00109	0.00356	CcSEcCtD
Buprenorphine—Hyperhidrosis—Liotrix—hypothyroidism	0.00108	0.00353	CcSEcCtD
Buprenorphine—CYP2C9—heart—hypothyroidism	0.00108	0.0129	CbGeAlD
Buprenorphine—Pruritus—Levothyroxine—hypothyroidism	0.00107	0.00351	CcSEcCtD
Buprenorphine—Pruritus—Dextrothyroxine—hypothyroidism	0.00107	0.00351	CcSEcCtD
Buprenorphine—Anorexia—Liotrix—hypothyroidism	0.00106	0.00348	CcSEcCtD
Buprenorphine—Hypotension—Liotrix—hypothyroidism	0.00104	0.00341	CcSEcCtD
Buprenorphine—CYP2C19—blood—hypothyroidism	0.00104	0.0124	CbGeAlD
Buprenorphine—Diarrhoea—Levothyroxine—hypothyroidism	0.00104	0.00339	CcSEcCtD
Buprenorphine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00104	0.00339	CcSEcCtD
Buprenorphine—CYP2C9—cardiovascular system—hypothyroidism	0.00102	0.0122	CbGeAlD
Buprenorphine—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00102	0.00332	CcSEcCtD
Buprenorphine—CYP2C8—pituitary gland—hypothyroidism	0.00101	0.0121	CbGeAlD
Buprenorphine—Insomnia—Liotrix—hypothyroidism	0.00101	0.0033	CcSEcCtD
Buprenorphine—Paraesthesia—Liotrix—hypothyroidism	0.001	0.00328	CcSEcCtD
Buprenorphine—Dyspnoea—Liotrix—hypothyroidism	0.000995	0.00325	CcSEcCtD
Buprenorphine—ABCG2—pituitary gland—hypothyroidism	0.000987	0.0118	CbGeAlD
Buprenorphine—Decreased appetite—Liotrix—hypothyroidism	0.000971	0.00317	CcSEcCtD
Buprenorphine—Vomiting—Dextrothyroxine—hypothyroidism	0.000965	0.00315	CcSEcCtD
Buprenorphine—Vomiting—Levothyroxine—hypothyroidism	0.000965	0.00315	CcSEcCtD
Buprenorphine—Fatigue—Liotrix—hypothyroidism	0.000963	0.00315	CcSEcCtD
Buprenorphine—Rash—Levothyroxine—hypothyroidism	0.000957	0.00313	CcSEcCtD
Buprenorphine—Rash—Dextrothyroxine—hypothyroidism	0.000957	0.00313	CcSEcCtD
Buprenorphine—Dermatitis—Levothyroxine—hypothyroidism	0.000956	0.00312	CcSEcCtD
Buprenorphine—Dermatitis—Dextrothyroxine—hypothyroidism	0.000956	0.00312	CcSEcCtD
Buprenorphine—Constipation—Liotrix—hypothyroidism	0.000955	0.00312	CcSEcCtD
Buprenorphine—Headache—Dextrothyroxine—hypothyroidism	0.000951	0.00311	CcSEcCtD
Buprenorphine—Headache—Levothyroxine—hypothyroidism	0.000951	0.00311	CcSEcCtD
Buprenorphine—Feeling abnormal—Liotrix—hypothyroidism	0.00092	0.00301	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Liotrix—hypothyroidism	0.000913	0.00298	CcSEcCtD
Buprenorphine—CYP2C8—blood—hypothyroidism	0.000906	0.0108	CbGeAlD
Buprenorphine—Nausea—Dextrothyroxine—hypothyroidism	0.000902	0.00295	CcSEcCtD
Buprenorphine—Nausea—Levothyroxine—hypothyroidism	0.000902	0.00295	CcSEcCtD
Buprenorphine—Urticaria—Liotrix—hypothyroidism	0.000887	0.0029	CcSEcCtD
Buprenorphine—Body temperature increased—Liotrix—hypothyroidism	0.000883	0.00288	CcSEcCtD
Buprenorphine—Abdominal pain—Liotrix—hypothyroidism	0.000883	0.00288	CcSEcCtD
Buprenorphine—ABCG2—adrenal gland—hypothyroidism	0.000882	0.0105	CbGeAlD
Buprenorphine—ABCG2—blood—hypothyroidism	0.000881	0.0105	CbGeAlD
Buprenorphine—ABCG2—thyroid gland—hypothyroidism	0.000851	0.0102	CbGeAlD
Buprenorphine—CYP1A2—blood—hypothyroidism	0.000848	0.0101	CbGeAlD
Buprenorphine—Hypersensitivity—Liotrix—hypothyroidism	0.000823	0.00269	CcSEcCtD
Buprenorphine—ABCG2—female gonad—hypothyroidism	0.000822	0.00982	CbGeAlD
Buprenorphine—CYP1A2—thyroid gland—hypothyroidism	0.000819	0.00978	CbGeAlD
Buprenorphine—CYP3A5—blood—hypothyroidism	0.000818	0.00977	CbGeAlD
Buprenorphine—CYP2C19—liver—hypothyroidism	0.000812	0.0097	CbGeAlD
Buprenorphine—CYP2C9—blood—hypothyroidism	0.000805	0.00962	CbGeAlD
Buprenorphine—Asthenia—Liotrix—hypothyroidism	0.000801	0.00262	CcSEcCtD
Buprenorphine—Pruritus—Liotrix—hypothyroidism	0.00079	0.00258	CcSEcCtD
Buprenorphine—Diarrhoea—Liotrix—hypothyroidism	0.000764	0.0025	CcSEcCtD
Buprenorphine—CYP3A5—female gonad—hypothyroidism	0.000763	0.00911	CbGeAlD
Buprenorphine—CYP2C8—testis—hypothyroidism	0.00075	0.00896	CbGeAlD
Buprenorphine—Dizziness—Liotrix—hypothyroidism	0.000738	0.00241	CcSEcCtD
Buprenorphine—ABCG2—testis—hypothyroidism	0.000729	0.00871	CbGeAlD
Buprenorphine—Vomiting—Liotrix—hypothyroidism	0.00071	0.00232	CcSEcCtD
Buprenorphine—CYP2C8—liver—hypothyroidism	0.000709	0.00847	CbGeAlD
Buprenorphine—Rash—Liotrix—hypothyroidism	0.000704	0.0023	CcSEcCtD
Buprenorphine—Dermatitis—Liotrix—hypothyroidism	0.000703	0.0023	CcSEcCtD
Buprenorphine—Headache—Liotrix—hypothyroidism	0.000699	0.00229	CcSEcCtD
Buprenorphine—ABCG2—liver—hypothyroidism	0.000689	0.00823	CbGeAlD
Buprenorphine—ABCG2—cerebellum—hypothyroidism	0.000673	0.00804	CbGeAlD
Buprenorphine—CYP1A2—liver—hypothyroidism	0.000663	0.00792	CbGeAlD
Buprenorphine—Nausea—Liotrix—hypothyroidism	0.000663	0.00217	CcSEcCtD
Buprenorphine—CYP3A5—liver—hypothyroidism	0.00064	0.00764	CbGeAlD
Buprenorphine—CYP2C9—liver—hypothyroidism	0.00063	0.00752	CbGeAlD
Buprenorphine—CYP3A4—blood—hypothyroidism	0.000614	0.00733	CbGeAlD
Buprenorphine—CYP2D6—blood—hypothyroidism	0.000604	0.00722	CbGeAlD
Buprenorphine—ABCB1—adrenal cortex—hypothyroidism	0.000602	0.00719	CbGeAlD
Buprenorphine—ABCB1—heart—hypothyroidism	0.000582	0.00696	CbGeAlD
Buprenorphine—CYP2D6—female gonad—hypothyroidism	0.000563	0.00673	CbGeAlD
Buprenorphine—ABCB1—cardiovascular system—hypothyroidism	0.00055	0.00656	CbGeAlD
Buprenorphine—CYP2D6—testis—hypothyroidism	0.0005	0.00597	CbGeAlD
Buprenorphine—ABCB1—gonad—hypothyroidism	0.000499	0.00596	CbGeAlD
Buprenorphine—ABCB1—pituitary gland—hypothyroidism	0.000487	0.00581	CbGeAlD
Buprenorphine—CYP3A4—liver—hypothyroidism	0.00048	0.00574	CbGeAlD
Buprenorphine—CYP2D6—liver—hypothyroidism	0.000472	0.00564	CbGeAlD
Buprenorphine—CYP2D6—cerebellum—hypothyroidism	0.000462	0.00551	CbGeAlD
Buprenorphine—ABCB1—adrenal gland—hypothyroidism	0.000435	0.00519	CbGeAlD
Buprenorphine—ABCB1—blood—hypothyroidism	0.000435	0.00519	CbGeAlD
Buprenorphine—ABCB1—thyroid gland—hypothyroidism	0.000419	0.00501	CbGeAlD
Buprenorphine—ABCB1—female gonad—hypothyroidism	0.000405	0.00484	CbGeAlD
Buprenorphine—ABCB1—testis—hypothyroidism	0.000359	0.00429	CbGeAlD
Buprenorphine—ABCB1—liver—hypothyroidism	0.00034	0.00406	CbGeAlD
Buprenorphine—ABCB1—cerebellum—hypothyroidism	0.000332	0.00397	CbGeAlD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—AVP—hypothyroidism	5.21e-05	0.00496	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—TSHB—hypothyroidism	5.14e-05	0.00491	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—TSHR—hypothyroidism	5.14e-05	0.00491	CbGpPWpGaD
Buprenorphine—CYP3A7—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	5.13e-05	0.00489	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—TRH—hypothyroidism	5.06e-05	0.00483	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	5.01e-05	0.00477	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	5.01e-05	0.00477	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—IYD—hypothyroidism	4.83e-05	0.00461	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	4.8e-05	0.00457	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CLTC—hypothyroidism	4.74e-05	0.00452	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR ligand binding—POMC—hypothyroidism	4.72e-05	0.0045	CbGpPWpGaD
Buprenorphine—CYP2A6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	4.7e-05	0.00448	CbGpPWpGaD
Buprenorphine—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	4.57e-05	0.00436	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—TSHB—hypothyroidism	4.51e-05	0.0043	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—TSHR—hypothyroidism	4.51e-05	0.0043	CbGpPWpGaD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—AVP—hypothyroidism	4.4e-05	0.0042	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—TRH—hypothyroidism	4.28e-05	0.00408	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—VAV3—hypothyroidism	4.17e-05	0.00397	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ATP5O—hypothyroidism	4.11e-05	0.00392	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TRH—hypothyroidism	4.1e-05	0.00391	CbGpPWpGaD
Buprenorphine—CYP2C18—Biological oxidations—POMC—hypothyroidism	4.1e-05	0.00391	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AVP—hypothyroidism	4.01e-05	0.00383	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	3.98e-05	0.0038	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	3.97e-05	0.00379	CbGpPWpGaD
Buprenorphine—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	3.96e-05	0.00378	CbGpPWpGaD
Buprenorphine—OPRD1—Peptide ligand-binding receptors—POMC—hypothyroidism	3.94e-05	0.00376	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—TPO—hypothyroidism	3.86e-05	0.00368	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—IYD—hypothyroidism	3.82e-05	0.00364	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—TSHB—hypothyroidism	3.81e-05	0.00364	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—TSHR—hypothyroidism	3.81e-05	0.00364	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—VAV3—hypothyroidism	3.78e-05	0.00361	CbGpPWpGaD
Buprenorphine—CYP3A5—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	3.71e-05	0.00353	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TSHB—hypothyroidism	3.65e-05	0.00348	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TSHR—hypothyroidism	3.65e-05	0.00348	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AVP—hypothyroidism	3.65e-05	0.00348	CbGpPWpGaD
Buprenorphine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	3.53e-05	0.00337	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	3.49e-05	0.00333	CbGpPWpGaD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—POMC—hypothyroidism	3.46e-05	0.0033	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—POMC—hypothyroidism	3.33e-05	0.00317	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—TRH—hypothyroidism	3.26e-05	0.00311	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SH2B3—hypothyroidism	3.26e-05	0.00311	CbGpPWpGaD
Buprenorphine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	3.25e-05	0.0031	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ATP5O—hypothyroidism	3.25e-05	0.0031	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—IYD—hypothyroidism	3.24e-05	0.00309	CbGpPWpGaD
Buprenorphine—UGT1A9—Biological oxidations—POMC—hypothyroidism	3.24e-05	0.00309	CbGpPWpGaD
Buprenorphine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	3.22e-05	0.00307	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—IYD—hypothyroidism	3.21e-05	0.00306	CbGpPWpGaD
Buprenorphine—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	3.21e-05	0.00306	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TPO—hypothyroidism	3.05e-05	0.00291	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—AVP—hypothyroidism	3.03e-05	0.00289	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TRH—hypothyroidism	2.96e-05	0.00283	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	2.95e-05	0.00281	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—IYD—hypothyroidism	2.94e-05	0.00281	CbGpPWpGaD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—POMC—hypothyroidism	2.92e-05	0.00279	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—POMC—hypothyroidism	2.92e-05	0.00278	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—TSHB—hypothyroidism	2.91e-05	0.00277	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—TSHR—hypothyroidism	2.91e-05	0.00277	CbGpPWpGaD
Buprenorphine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	2.86e-05	0.00273	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—TRH—hypothyroidism	2.86e-05	0.00273	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	2.83e-05	0.0027	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ATP5O—hypothyroidism	2.76e-05	0.00263	CbGpPWpGaD
Buprenorphine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	2.75e-05	0.00263	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ATP5O—hypothyroidism	2.73e-05	0.0026	CbGpPWpGaD
Buprenorphine—CYP3A7—Biological oxidations—POMC—hypothyroidism	2.72e-05	0.0026	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—POMC—hypothyroidism	2.67e-05	0.00254	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—AVP—hypothyroidism	2.66e-05	0.00254	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	2.65e-05	0.00252	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TSHB—hypothyroidism	2.64e-05	0.00252	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TSHR—hypothyroidism	2.64e-05	0.00252	CbGpPWpGaD
Buprenorphine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	2.63e-05	0.00251	CbGpPWpGaD
Buprenorphine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	2.61e-05	0.00249	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TRH—hypothyroidism	2.6e-05	0.00248	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	2.59e-05	0.00247	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TPO—hypothyroidism	2.59e-05	0.00247	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TPO—hypothyroidism	2.57e-05	0.00245	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—TSHR—hypothyroidism	2.55e-05	0.00243	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—TSHB—hypothyroidism	2.55e-05	0.00243	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ATP5O—hypothyroidism	2.5e-05	0.00239	CbGpPWpGaD
Buprenorphine—CYP2A6—Biological oxidations—POMC—hypothyroidism	2.5e-05	0.00238	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—POMC—hypothyroidism	2.47e-05	0.00235	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—POMC—hypothyroidism	2.42e-05	0.00231	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—TRH—hypothyroidism	2.42e-05	0.00231	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PRL—hypothyroidism	2.42e-05	0.0023	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TPO—hypothyroidism	2.35e-05	0.00224	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—IYD—hypothyroidism	2.32e-05	0.00221	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	2.32e-05	0.00221	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TSHB—hypothyroidism	2.32e-05	0.00221	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TSHR—hypothyroidism	2.32e-05	0.00221	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AVP—hypothyroidism	2.25e-05	0.00214	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VAV3—hypothyroidism	2.24e-05	0.00213	CbGpPWpGaD
Buprenorphine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	2.23e-05	0.00213	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TRH—hypothyroidism	2.2e-05	0.00209	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—TSHR—hypothyroidism	2.15e-05	0.00205	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—TSHB—hypothyroidism	2.15e-05	0.00205	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AVP—hypothyroidism	2.15e-05	0.00205	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	2.15e-05	0.00205	CbGpPWpGaD
Buprenorphine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	2.12e-05	0.00203	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CLTC—hypothyroidism	2.02e-05	0.00193	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—POMC—hypothyroidism	2.01e-05	0.00192	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—IYD—hypothyroidism	2.01e-05	0.00192	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ATP5O—hypothyroidism	1.97e-05	0.00188	CbGpPWpGaD
Buprenorphine—CYP3A5—Biological oxidations—POMC—hypothyroidism	1.97e-05	0.00188	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	1.96e-05	0.00187	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TSHB—hypothyroidism	1.96e-05	0.00187	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TSHR—hypothyroidism	1.96e-05	0.00187	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	1.92e-05	0.00183	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TPO—hypothyroidism	1.86e-05	0.00177	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—IYD—hypothyroidism	1.8e-05	0.00171	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—TSHB—hypothyroidism	1.79e-05	0.00171	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—VAV3—hypothyroidism	1.78e-05	0.0017	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CLTC—hypothyroidism	1.78e-05	0.00169	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—POMC—hypothyroidism	1.77e-05	0.00169	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—IYD—hypothyroidism	1.75e-05	0.00167	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TRH—hypothyroidism	1.75e-05	0.00167	CbGpPWpGaD
Buprenorphine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	1.72e-05	0.00164	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AVP—hypothyroidism	1.71e-05	0.00163	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ATP5O—hypothyroidism	1.71e-05	0.00163	CbGpPWpGaD
Buprenorphine—CYP2C8—Biological oxidations—POMC—hypothyroidism	1.7e-05	0.00163	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—IYD—hypothyroidism	1.65e-05	0.00157	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—IYD—hypothyroidism	1.64e-05	0.00156	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—VAV3—hypothyroidism	1.62e-05	0.00154	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TPO—hypothyroidism	1.61e-05	0.00153	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3C2A—hypothyroidism	1.59e-05	0.00152	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TSHB—hypothyroidism	1.56e-05	0.00149	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TSHR—hypothyroidism	1.56e-05	0.00149	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—VAV3—hypothyroidism	1.56e-05	0.00149	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AVP—hypothyroidism	1.56e-05	0.00148	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TRH—hypothyroidism	1.53e-05	0.00146	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ATP5O—hypothyroidism	1.53e-05	0.00146	CbGpPWpGaD
Buprenorphine—CYP2C19—Biological oxidations—POMC—hypothyroidism	1.52e-05	0.00145	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—AVP—hypothyroidism	1.51e-05	0.00144	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AVP—hypothyroidism	1.5e-05	0.00143	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CLTC—hypothyroidism	1.5e-05	0.00143	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—POMC—hypothyroidism	1.49e-05	0.00142	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ATP5O—hypothyroidism	1.49e-05	0.00142	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.49e-05	0.00142	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TPO—hypothyroidism	1.44e-05	0.00137	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—POMC—hypothyroidism	1.43e-05	0.00136	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—VAV3—hypothyroidism	1.42e-05	0.00135	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TSHB—hypothyroidism	1.41e-05	0.00135	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ATP5O—hypothyroidism	1.4e-05	0.00134	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TPO—hypothyroidism	1.4e-05	0.00134	CbGpPWpGaD
Buprenorphine—CYP2D6—Biological oxidations—POMC—hypothyroidism	1.4e-05	0.00133	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—IYD—hypothyroidism	1.4e-05	0.00133	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ATP5O—hypothyroidism	1.39e-05	0.00133	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SH2B3—hypothyroidism	1.39e-05	0.00133	CbGpPWpGaD
Buprenorphine—CYP2C9—Biological oxidations—POMC—hypothyroidism	1.39e-05	0.00132	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IGF1—hypothyroidism	1.38e-05	0.00131	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TSHB—hypothyroidism	1.37e-05	0.0013	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TSHR—hypothyroidism	1.37e-05	0.0013	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AVP—hypothyroidism	1.36e-05	0.0013	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—SLC5A5—hypothyroidism	1.34e-05	0.00128	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.33e-05	0.00127	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TPO—hypothyroidism	1.32e-05	0.00126	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—VAV3—hypothyroidism	1.32e-05	0.00126	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	1.31e-05	0.00125	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TPO—hypothyroidism	1.31e-05	0.00125	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TRH—hypothyroidism	1.3e-05	0.00124	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AVP—hypothyroidism	1.27e-05	0.00121	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3C2A—hypothyroidism	1.26e-05	0.0012	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.24e-05	0.00119	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SH2B3—hypothyroidism	1.22e-05	0.00116	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.21e-05	0.00116	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TSHB—hypothyroidism	1.2e-05	0.00114	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—VAV3—hypothyroidism	1.2e-05	0.00114	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ATP5O—hypothyroidism	1.19e-05	0.00113	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TSHB—hypothyroidism	1.19e-05	0.00113	CbGpPWpGaD
Buprenorphine—CYP1A2—Biological oxidations—POMC—hypothyroidism	1.19e-05	0.00113	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TSHB—hypothyroidism	1.16e-05	0.0011	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TSHR—hypothyroidism	1.16e-05	0.0011	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AVP—hypothyroidism	1.15e-05	0.0011	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—POMC—hypothyroidism	1.14e-05	0.00109	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TPO—hypothyroidism	1.12e-05	0.00107	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TSHB—hypothyroidism	1.09e-05	0.00104	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—IYD—hypothyroidism	1.08e-05	0.00103	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3C2A—hypothyroidism	1.07e-05	0.00102	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3C2A—hypothyroidism	1.06e-05	0.00101	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—SLC5A5—hypothyroidism	1.06e-05	0.00101	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	1.04e-05	0.000988	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	1.04e-05	0.000988	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—POMC—hypothyroidism	1.03e-05	0.000986	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PRL—hypothyroidism	1.03e-05	0.000984	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SH2B3—hypothyroidism	1.03e-05	0.000983	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—POMC—hypothyroidism	9.98e-06	0.000952	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3C2A—hypothyroidism	9.71e-06	0.000926	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VAV3—hypothyroidism	9.54e-06	0.00091	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AVP—hypothyroidism	9.19e-06	0.000877	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ATP5O—hypothyroidism	9.18e-06	0.000875	CbGpPWpGaD
Buprenorphine—CYP3A4—Biological oxidations—POMC—hypothyroidism	9.15e-06	0.000873	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—POMC—hypothyroidism	9.07e-06	0.000865	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PRL—hypothyroidism	9.04e-06	0.000862	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—SLC5A5—hypothyroidism	8.98e-06	0.000856	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—SLC5A5—hypothyroidism	8.9e-06	0.000849	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TPO—hypothyroidism	8.63e-06	0.000823	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TSHB—hypothyroidism	8.59e-06	0.00082	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—POMC—hypothyroidism	8.44e-06	0.000805	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VAV3—hypothyroidism	8.37e-06	0.000798	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	8.16e-06	0.000778	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—SLC5A5—hypothyroidism	8.16e-06	0.000778	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AVP—hypothyroidism	8.06e-06	0.000769	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—POMC—hypothyroidism	7.66e-06	0.000731	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	7.66e-06	0.00073	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PRL—hypothyroidism	7.64e-06	0.000729	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TSHB—hypothyroidism	7.44e-06	0.00071	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VAV3—hypothyroidism	7.07e-06	0.000674	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—POMC—hypothyroidism	7e-06	0.000668	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AVP—hypothyroidism	6.81e-06	0.00065	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TSHB—hypothyroidism	6.64e-06	0.000634	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	6.63e-06	0.000633	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	6.55e-06	0.000624	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TSHB—hypothyroidism	6.48e-06	0.000618	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—SLC5A5—hypothyroidism	6.43e-06	0.000614	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TSHB—hypothyroidism	6.11e-06	0.000583	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—POMC—hypothyroidism	6.11e-06	0.000583	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TSHB—hypothyroidism	6.06e-06	0.000578	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3C2A—hypothyroidism	5.92e-06	0.000565	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IGF1—hypothyroidism	5.88e-06	0.00056	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.84e-06	0.000557	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3C2A—hypothyroidism	5.78e-06	0.000551	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—SLC5A5—hypothyroidism	5.57e-06	0.000531	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—POMC—hypothyroidism	5.54e-06	0.000528	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	5.45e-06	0.000519	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	5.4e-06	0.000515	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—POMC—hypothyroidism	5.36e-06	0.000511	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.33e-06	0.000508	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TSHB—hypothyroidism	5.18e-06	0.000494	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IGF1—hypothyroidism	5.15e-06	0.000491	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—SLC5A5—hypothyroidism	4.97e-06	0.000474	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—SLC5A5—hypothyroidism	4.85e-06	0.000463	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—POMC—hypothyroidism	4.7e-06	0.000448	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—POMC—hypothyroidism	4.66e-06	0.000444	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	4.61e-06	0.00044	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—SLC5A5—hypothyroidism	4.57e-06	0.000436	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	4.55e-06	0.000434	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—SLC5A5—hypothyroidism	4.53e-06	0.000432	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—POMC—hypothyroidism	4.53e-06	0.000432	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1—hypothyroidism	4.35e-06	0.000415	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—POMC—hypothyroidism	4.27e-06	0.000407	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TSHB—hypothyroidism	4e-06	0.000381	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC5A5—hypothyroidism	3.88e-06	0.00037	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	3.56e-06	0.00034	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—POMC—hypothyroidism	3.37e-06	0.000321	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC5A5—hypothyroidism	2.99e-06	0.000285	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—POMC—hypothyroidism	2.92e-06	0.000278	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—POMC—hypothyroidism	2.6e-06	0.000248	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—POMC—hypothyroidism	2.54e-06	0.000242	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—POMC—hypothyroidism	2.39e-06	0.000228	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—POMC—hypothyroidism	2.37e-06	0.000226	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—POMC—hypothyroidism	2.03e-06	0.000193	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—POMC—hypothyroidism	1.56e-06	0.000149	CbGpPWpGaD
